Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
08 April 2021Website:
http://reneopharma.comNext earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 28 Jun 2024 20:38:00 GMTDividend
Analysts recommendations
Institutional Ownership
RPHM Latest News
NEW YORK , June 24, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and is investigating Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), relating to its proposed merger with OnKure, Inc. Under the terms of the agreement, Reneo stockholders are expected to own approximately 31% of the combined company.
NEW YORK, June 21, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and is investigating Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM ), relating to its proposed merger with OnKure, Inc. Under the terms of the agreement, Reneo stockholders are expected to own approximately 31% of the combined company.
Reneo (RPHM) loses 83% following the failure of the mid-stage pivotal study of its only pipeline candidate, mavodelpar, to treat primary mitochondrial myopathies in adults. It cuts the workforce by 70%.
Reneo Pharmaceuticals is developing mitochondrial disease therapies, with its lead program being mavodelpar or REN001. Mavodelpar has shown promising results in increasing fatty acid oxidation and improving muscle strength in clinical trials. The company expects topline results from a pivotal trial in primary mitochondrial myopathy in 4Q23, with potential approval and launch in late 2024.
What type of business is Reneo Pharmaceuticals?
Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
What sector is Reneo Pharmaceuticals in?
Reneo Pharmaceuticals is in the Healthcare sector
What industry is Reneo Pharmaceuticals in?
Reneo Pharmaceuticals is in the Biotechnology industry
What country is Reneo Pharmaceuticals from?
Reneo Pharmaceuticals is headquartered in United States
When did Reneo Pharmaceuticals go public?
Reneo Pharmaceuticals initial public offering (IPO) was on 08 April 2021
What is Reneo Pharmaceuticals website?
https://reneopharma.com
Is Reneo Pharmaceuticals in the S&P 500?
No, Reneo Pharmaceuticals is not included in the S&P 500 index
Is Reneo Pharmaceuticals in the NASDAQ 100?
No, Reneo Pharmaceuticals is not included in the NASDAQ 100 index
Is Reneo Pharmaceuticals in the Dow Jones?
No, Reneo Pharmaceuticals is not included in the Dow Jones index
When does Reneo Pharmaceuticals report earnings?
The next expected earnings date for Reneo Pharmaceuticals is 09 August 2024